The KEEPER™ trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

Epilepsy Research

Volumn 54, Issue 2-3, 2003, Pages 153-161

  Morrell, M J ^a   Leppik, I ^b   French, J ^c   Ferrendelli, J ^d   Han, J ^e   Magnus, L ^e  

^a NEUROLOGICAL INSTITUTE   (United States)

^b MINCEP Epilepsy Care   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UCB PHARMA   (Belgium)

Author keywords

Adjunctive therapy; Antiepileptic; Levetiracetam; Partial epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; DRUG DERIVATIVE; PIRACETAM;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; AGITATION; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPERSONALIZATION; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; FREQUENCY ANALYSIS; HEADACHE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MORBIDITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEIZURE THRESHOLD; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; VERTIGO; COMMUNITY CARE; DRUG COMBINATION; FOCAL EPILEPSY; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; COMMUNITY HEALTH SERVICES; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES;

EID: 0038094419     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(03)00080-9     Document Type: Article

References (18)

1. Ben-Menachem, E., Falter, U., for the European Levetiracetam Study Group, 2000. Efficacy and tolerability of levetiracetam 3000 mg per day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41, 1276-1283.
2. Betts T., Waegemans T., Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 9:2000;80-87.
3. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg per day in partial epilepsy. Epilepsy Res. 48:2002;77-89.
4. Browne T.R., Szabo G.K., Leppik I.E., Josephs E., Paz J., Baltes E., Jensen C.M. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J. Clin. Pharmacol. 40:2000;1-6.
5. Cereghino, J.J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L.J., Leppik, I., for the United States Levetiracetam Study Group, 2000. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 55, 236-242.
6. Coupez, R., Nicolas, J.-M., Browne, T.R., 2002. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia, in press.
7. Cramer, J.A., Arrigo, C., Van Hammée, G., Gauer, L.J., Cereghino, J.J., for the N132 Study Group, 2000. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41, 868-874.
8. Data on file. UCB Pharma. Braine-l'Alleud, Belgium.
9. Giuliano R.A., Hiersemenzel R., Baltes E., Johnscher G., Janik F., Weber W. Influence of a new antiepileptic drug (levetiracetam, ucb L059) on the pharmacokinetics and pharmacodynamics of oral contraceptives. Epilepsia. 37(Suppl. 4):1996;90.
10. ILAE, 1989. Commission on Classification and Terminology of the International League against Epilepsy, 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30, 389-399.
11. Keppra™ (levetiracetam) tablets, 2002. Physicians Desk Reference, 56th ed. Medical Economics Co., Inc., Montvale, NJ, pp. 3314-3317.
12. Krakow K., Walker M., Otoul C., Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 56:2001;1772-1774.
13. Levy R.H., Ragueneau-Majlessi I., Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 46:2001;93-99.
14. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85:2000;77-85.
15. Perucca E., Gidal B.E., Ledent E., Baltes E. Levetiracetam does not interact with other antiepileptic drugs. Epilepsia. 37(Suppl. 4):1996;90.
16. Ragueneau-Majlessi I., Levy R.H., Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamics and pharmacokinetic profiles of warfarin. Epilepsy Res. 47:2001;55-63.
17. Ragueneau-Majlessi I., Levy R.H., Janik F. Levetiracetam does not alter the parmacokinetics of an oral contraceptive in healthy women. Epilepsia. 43:2002;697-702.
18. Shovron, S.D., Löwenthal, A., Janz, D., Bielen, E., Loiseau, P., for the European Levetiracetam Study Group, 2000. Multicenter double-blind randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41, 1179-1186.